Background: Angiopoietin-like-3 (ANGPTL3) expression is increased in glomerular podocytes of nephrotic syndrome. We hypothesize whether ANGPTL3 plays an important role in podocyte injury and promoting proteinuria.
l ong-term and significant proteinuria is closely related to the progressive decline of kidney function (1) . Podocyte injury is believed to be important in promoting proteinuria. Previous studies concerning podocyte biology have revealed the molecular mechanisms behind several genetic disorders (2) . Recent studies, however, have explored several circulating or podocytesecreted proteins, such as the serum-soluble urokinase receptor (3), vascular endothelial growth factor (4) , and angiopoietinlike-4 (5), which result in damage to the glomerular filtration barrier, probably via an autocrine or paracrine pathway. These findings have attracted the attention of many researchers.
In 2001, using a microarray study, we found that angiopoietin-like-3 (ANGPTL3) expression was significantly increased in the kidney tissue of children with nephrotic syndrome, who characterized with massive proteinuria and diffuse effacement of podocyte foot processes. ANGPTL3 is a secreted protein with a characteristic angiopoietin structure: a signal peptide for secretion, a helical domain that forms coiled coils (CLD), and a C-terminal globular fibrinogen-like domain (FLD) (6) . The CLD inhibits lipase activity, leading to elevated plasma triglyceride levels in mice (7) , and the FLD induces angiogenesis by binding to integrin αVβ3 (8) . ANGPTL3 is mainly synthesized by hepatocytes and secreted into the circulation, acting on liver X receptors in fat cells (9) . Under normal conditions, ANGPTL3 is expressed in low amounts in the kidney, and its significance in proteinuria is unknown.
In our previous study, we found upregulation of ANGPTL3 expression not only in glomeruli of children with nephrotic syndrome (10) , but also in glomerular podocytes of rats with adriamycin-induced nephropathy (11) , and in cultured mouse podocytes treated with adriamycin or puromycin aminonucleoside (PAN) (12, 13) . Moreover, we found that upregulating podocyte ANGPTL3 expression in vitro stimulates podocyte F-actin rearrangement (14) and increases podocyte motility (13) . These experiments indicate that an increased level of ANGPTL3 expression affects podocyte cytoskeleton and function and may be related to promoting proteinuria.
To further clarify whether the altered ANGPTL3 expression in the kidney is merely a satellite phenomenon of proteinuria or an important regulatory factor that influences the disease occurrence and outcome, we investigated the role of ANGPTL3 in Angptl3 −/− mice and established a model of proteinuria in mice. We conducted pathological, cellular, and molecular analyses to answer these questions, and our findings help elaborate the mechanism by which ANGPTL3 regulates the occurrence and development of proteinuria via interacting with and activating integrin β3, thus affecting the podocyte cytoskeleton. Finally, this study develops new ideas
Angptl3
+/-mice were purchased from Mutant Mouse Regional Resource Centers (MMRRC), and Angptl3 −/− (KO) mice were bred by mating heterozygous mice with heterozygous mice. Genotyping was performed by PCR (Figure 1a) . Immunofluorescence confirmed no ANGPTL3 expression in the liver or kidney of KO mice (Figure 1b) .
When comparing KO mice and wild-type (WT) mice phenotypes, we found that the KO mice had a body shape that was similar to that of the WT mice as previously reported (15) , and there was no difference in their body weights at 8 wk of age (KO 26.02 ± 0.44 g vs. WT 25.73 ± 0.70 g, P > 0.05). As to the urinary albumin level, testing strips and SDS-PAGE showed an absence of albuminuria in KO mice and WT mice. The plasma albumin level was normal in both groups (KO 29.85 ± 0.71 g/l vs. WT 28.75 ± 0.41 g/l, P > 0.05), while the plasma lipid levels were significantly lower in the KO mice than in the WT mice, as predicted, due to the lipase inhibitory effect of ANGPTL3 (cholesterol: KO 1.82 ± 0.15 mmol/l vs. WT 2.86 ± 0.13 mmol/l, P < 0.01; triglyceride KO 0.48 ± 0.02 mmol/l vs. WT 0.87 ± 0.12 mmol/l, P < 0.01) (Figure 1c) . The glomeruli of the KO mice stained with PAS showed the same normal structure as the WT mice under light microscopy, and the ultrastructure of the podocytes showed no effacement of foot processes or proliferation of microvilli under transmission electron microscopy (TEM) or scanning electron microscopy (SEM) in either group of mice (Figure 1d) Adriamycin is commonly used in mice to induce podocyte injury and proteinuria. However, even at a high dose of adriamycin, proteinuria cannot be induced in C57BL/6J male mice, while it can be induced in the female mice with a 25 mg/kg dose via tail vein injection, and these mice begin to die at day 5 after injection (16) . Therefore, in the present study, we intravenously injected adriamycin at a high dose of 25 mg/kg and successfully established for the first time an adriamycin-induced podocyte injury and proteinuria model in WT female mice with a B6;129S5 gene background; the affected mice exhibited hypoalbuminemia, massive proteinuria, hyperlipidemia, and The glomeruli of the KO mice and WT mice were stained with PAS (×100, bar = 100 μm), and the ultrastructure of the podocytes were examined using transmission electron microscopy (TEM, x10,000, bar = 1 μm) and scanning electron microscopy (SEM, ×5,000, bar = 5 μm) in two groups of mice. the diffuse effacement of foot processes in the podocytes. Six days after the intravenous injection of adriamycin, the plasma albumin levels of the WT mice fell to 23.8 ± 0.3 g/l, which was significantly lower than that of the saline-injected WT group (29.52 ± 0.79 g/l, P < 0.001). The urine albumin:creatinine ratio of the adriamycin-injected WT mice was 272.48 ± 1.84 μg/mg, which was significantly higher than that of the saline-injected WT group (4.11 ± 0.78 μg/mg, P < 0.0001). The plasma cholesterol level of the adriamycin-injected WT mice was 3.37 ± 0.18 mmol/l, which was significantly higher than that of the salineinjected WT group (2.06 ± 0.23 mmol/l, P < 0.005). The plasma triglyceride level of the adriamycin-injected WT mice was 1.2 ± 0.17 mmol/l, which was significantly higher than that of the saline-injected WT group (0.73 ± 0.08 mmol/l, P < 0.005) (Figure 2a ). In addition, the adriamycin-injected WT mice appeared to be significantly weaker than the saline-injected WT mice, as manifested by significantly sparser hair that was dull and prone to falling out, significantly reduced activity levels, and a curled body position.
Regarding the renal histopathological changes, no difference was found under light microscopy between the adriamycin-injected WT mice and the saline-injected WT mice, as manifested by the clear glomerular structure in both groups, as predicted. However, under TEM and SEM, the appearance of the podocytes between the two groups of mice was significantly different, as manifested by the significant effacement of the podocyte foot processes and the significant podocyte microvillus protrusion in the adriamycin-injected WT mice compared to the saline-injected controls (Figure 2b) .
In contrast, the adriamycin-injected KO mice presented entirely differently compared to the adriamycin-injected WT mice. The appearance of the adriamycin-injected KO mice was similar to the saline-injected WT mice. Interestingly, the adriamycin-injected KO mice did not show hypoalbuminemia, and their plasma albumin level was normal (30.14 ± 1.2 g/l), which was nearly 30% higher than that of the adriamycin-injected WT mice (23.8 ± 0.3 g/l; P < 0.005). The urine albumin:creatinine ratio of the adriamycininjected KO mice was 50.66 ± 1.05 μg/mg, which was fivefold lower than that of the adriamycin-injected WT mice (272.48 ± 1.84 μg/mg; P < 0.0001). The plasma triglyceride level of the adriamycin-injected KO mice was 0.38 ± 0.04 mmol/l, which was significantly lower than that of the adriamycin-injected WT mice (1.2 ± 0.17 mmol/l, P < 0.005). The plasma cholesterol level of the adriamycin-injected KO mice was 2.18 ± 0.14 mmol/l, which was also significantly lower than that of the adriamycin-injected WT mice (3.37 ± 0.18, P < 0.005) (Figure 2a) .
The renal histopathological changes showed no differences under light microscopy (clear glomerular structure) between the adriamycin-injected KO mice and the adriamycin-injected WT mice. However, TEM and SEM showed significant differences in the podocyte lesions between two groups, as manifested by the significant fusion of podocyte foot processes and significant podocyte microvillus protrusion in the adriamycin-injected WT mice and an almost normal podocyte structure in the adriamycin-injected KO mice (Figure 2b) . (17) . In our previous study, we found that integrin αVβ3 mediated F-Actin rearrangement through small GTPases Rac1 and RhoA, and integrin-mediated FAK/PI3K phosphorylation is important for Rac1 activation and podocytes lamellipodia formation (14) . Here, we hypothesized that the podocyte-secreted ANGPTL3 binds to and activates integrin β3 on the podocytes themselves, thereby inducing podocyte cytoskeletal rearrangement and regulating podocyte motility via this autocrine or paracrine pathway, promoting proteinuria.
To test this hypothesis, we firstly performed a confocal microscopy study and demonstrated the colocalization of ANGPTL3 and integrin β3 in cultured podocytes overexpressing ANGPTL3 (Figure 3a) . Coimmunoprecipitation (co-IP) showed that ANGPTL3 and integrin β3 formed a complex in cultured podocytes, indicating that ANGPTL3 binds to integrin β3 (Figure 3b) . Furthermore, we investigated whether ANGPTL3 activates integrin β3 in podocytes using AP5, a monoclonal antibody that specifically detects the active form of integrin β3 (18). The fluorescence-activated cell sorting (FACS) results showed that ANGPTL3 over-expression significantly increased the percentage of AP5 positive podocytes (P < 0.01). Meanwhile, ANGPTL3 knockdown significantly suppressed the increased AP5-positive cell percentage after treatment with adriamycin (P < 0.05, Figure 4a) . These results confirmed our hypothesis that ANGPTL3 interacts with and activates integrin β3 in podocytes. We also found colocalization of the ANGPTL3-AP5 complex in the lamellipodia of adriamycin-treated podocytes (Figure 4b) , which may indicate that ANGPTL3 is concentrated in the effaced podocyte foot processes, as we also confirmed in the podocytes of adriamycin-induced rats by immunogold staining (Figure 5 ).
ANGPTL3 Regulates α-Actinin-4 Expression in Cultured Mouse Podocytes
Actin filaments are important for maintaining normal podocyte morphology and motility (19) . We previously reported that ANGPTL3 induces podocyte F-actin rearrangement (14) . Alpha-actinin-4, an actin-modulating protein, can cross-link with F-actin to maintain the necessary polarity for actin bundle formation and is a downstream signal for integrin β3 (20) (21) (22) . Recent reports have also shown that either the upregulation or absence of α-actinin-4 in podocytes can lead to renal disease. Therefore, we further investigated the association between ANGTPL3 and α-actinin-4 in vitro. We found that ANGPTL3 significantly affected the mRNA and protein expression of α-actinin-4 (Figure 6 ), suggesting that ANGPTL3 may induce podocyte actin rearrangement by affecting α-actinin-4 expression. Additionally, the ANGPTL3 knockdown substantially inhibited the change of expression of α-actinin-4 for 24 h after adriamycin treatment (Figure 6 ). These data indicate that α-actinin-4 expression is affected in response to adriamycin in an ANGPTL3-dependent manner. Taken together, our findings indicate that ANGPTL3 significantly affects podocyte cytoskeleton dynamics and plays an important role in actin rearrangement.
Activation of the ANGPTL3-Integrin β3 Signaling Pathway in Patients With Nephrotic Syndrome
In vitro, we have found increased expression of ANGPTL3 activates integrin β3 and its downstream signaling pathway, leading to cytoskeleton rearrangement of podocytes. In mouse proteinuria model, we have demonstrated that deletion of ANGPTL3 has a protective effect on podocytes cytoskeleton and can reduce proteinuria. Therefore, we further investigated whether this interaction happened in human as well. Renal biopsy tissues from 30 patients with nephrotic syndrome (MCD, n = 16; FSGS, n = 7; IgA nephropathy, n = 4; and membrane nephropathy, n = 3) who presented with massive proteinuria and diffuse effacement of podocyte foot processes were studied. They were from 17 males and 13 females with an average age of 34.1 ± 15.9 y. We found an increased expression of ANGPTL3, integrin β3, and AP5 with confocal microscopy in all samples (Figure 7) , indicating that the ANGPTL3-induced activation of integrin β3 is involved in the development of foot process effacement and the rearrangement of the cytoskeleton in podocytes and may, thus, accelerate the development of proteinuria in patients with nephrotic syndrome.
DISCUSSION
In this report, we demonstrate in vivo a novel role for ANGPTL3 in podocyte injury and proteinuria. We found that the deletion of ANGPTL3 greatly attenuates proteinuria and podocyte injury in adriamycin-injected mice. Our in vitro studies indicate that ANGPTL3 can interact with and activate integrin β3 and its downstream signaling pathway and may therefore induce the rearrangement of the podocyte cytoskeleton by interfering with α-actinin-4. Furthermore, we demonstrated that the ANGPTL3 pathway is activated in the podocytes of patients with proteinuria disease such as nephrotic syndrome.
Our earlier studies revealed the increased expression of ANGPTL3 in the podocytes of children with nephrotic syndrome and of rats with adriamycin-induced nephropathy, as well as in adriamycin-or PAN-treated cultured podocytes. We have identified ANGPTL3-dependent regulation of podocyte motility in vitro (12, 13) . In this study, our in vivo experiments indicate that the deletion of ANGPTL3 can tremendously reduce proteinuria and preserve podocyte structure and function in adriamycin-injected mice, suggesting that ANGPTL3 can significantly affect the development of proteinuria by interfering with the podocyte cytoskeleton. Human studies have also supported this finding, as there is increased ANGPTL3 expression in the glomeruli of patients with diffuse effacement of foot processes in podocytes.
ANGPTL3 has been reported to directly bind to integrin β3 in human microvascular vein endothelial cells (8) , and integrin β3 activation in podocytes can promote the effacement of Articles podocyte foot processes (3, 17) and promote proteinuria. We previously further demonstrated integrin β3 mediated F-actin rearrangement through FAK/PI3K signaling pathway, causing particular lamellipodia formation in podocytes (14) . In this study, we demonstrated that ANGPTL3 changing podocyte morphology by interacting with and activating integrin β3 in podocytes, which was proven by the increased detection of AP5, a monoclonal antibody that specifically binds to the active form of integrin β3. Our experiments also indicated that ANGPTL3 regulates α-actinin-4 expression, involved in affecting podocyte cytoskeleton dynamics. Additionally, in human tissue, we also observed a correlation between the diffuse effacement of the foot processes and activation of the ANGPTL3-integrin β3 signaling pathway. All these results indicate that activation of the ANGPTL3 pathway in podocytes may induce cytoskeleton rearrangement and result in the effacement of foot processes and proteinuria. It is of note that Clement et al. recently reported that podocytes secreting ANGPTL4 play a vital role in nephrotic syndrome, possibly due to the reduced sialylation level of ANGPTL4 (5). It will be very interesting to further study the relationship between ANGPTL3 and ANGPTL4 in nephrotic syndrome.
In summary, we report a novel role for ANGPTL3 in podocyte injury regarding proteinuria and describe a novel mechanism for ANGPTL3, wherein ANGPTL3 is involved in the production of proteinuria by triggering integrin β3 and the downstream signaling pathway in podocytes; this may result in cytoskeletal rearrangement and the effacement of foot processes. This research helps to deepen the understanding of the potential involvement of angiopoietin-like proteins in proteinuria diseases and lays the foundation for further indepth research into the renoprotective effect of the Angptl3 knockout and the development of a molecular-targeted treatment of podocytes.
METHODS

Antibodies and Reagents
The antibodies and reagents used in this study are listed with their sources as follows: AP5 monoclonal antibody against active β3 integrin (Genetic Testing Institute, Waukesha, WI); polyclonal antibody against α-actinin-4 (Chemicon, Temecula, CA); monoclonal antibody against glyceraldehyde-phosphate dehydrogenase (GAPDH) (Santa Cruz Biotechnology, Dallas, TX); polyclonal antibody against ANGPTL3 (R&D Systems, Minneapolis, MN); fluorescein phalloidin for labeling F-actin (Invitrogen, Carlsbad, CA); and polyclonal antibody against synaptopodin (Sigma-Aldrich, St Louis, MO). Adriamycin was purchased from Pfizer (New York, NY). The expression of ANGPTL3 (green) and AP5 (red) in renal biopsy tissue of a patient with nephrotic syndrome with diffuse effacement of podocyte foot processes were examined using confocal immunofluorescence microscopy. Representative images of one 9-y-old boy with nephrotic syndrome (MCD) and a normal control are shown. bar = 100 μm for confocal immunofluorescence image and 500 nm for ECM. 
